Archived Bulletins

September 26, 2018

Published: September 26, 2018
Category: Trials

ND.210 A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Al one in Patients with Metastatic Colorectal Cance

Read More

Published: September 26, 2018
Category: News

On Wednesday September 19th 2018, CCTG's Director, Dr. Janet Dancey aired on the Blind Date with Knowledge radio show. During her interview Dr. Dancey talks about Evolving Clinical Trials through Collaboration. She discussed how the collaborative study of medical interventions in the treatment of cancer has expanded to also investigate how lifestyle, radiation, surgical, and smoke cessation interventions can affect the entire spectrum of cancer treatment.

Read More

CCTG publication
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G. Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (ONLINE). Ann Oncol mdy398, 2018.
 
Read More

September 10, 2018

Published: September 10, 2018
Category: Trials
Trial closure: MAC8 and HEC1
Please be aware that two trials have recently been permenantly closed:
  1. MAC8 (NSABP B-37): A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer.
  2. HEC1 (CALGB 80802): Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).
Read More

Published: September 10, 2018
Category: Trials
Trial Activation: CRC.8

The CRC.8 clinical trial is a Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High-Risk Anal Cancer, which has been centrally activated. This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.

Read More

Published: September 10, 2018
Category: Trials

The CCTG PA.7 trial: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma met its target accrual of 180 patients on 26-JUL-2018 and is now officially closed to accrual.

Read More

Published: September 10, 2018
Category: News

The Canadian Institute of Health Research (CIHR) has announced a project grant award of $860,628 over six years for a research project lead by the Canadian Cancer Trials Group (CCTG). The HN.10 study will investigate the potential benefits of the de-escalation of treatment for patients with tonsil cancer.

Oropharyngeal squamous cell carcinoma (OPSCC) is one of the most common forms of head and neck cancer. Although this type cancer is often associated with other risk factors, OPSCC related to human papillomavirus (HPV) infection has seen a dramatic increase globally.

Read more >

Read More

Published: September 10, 2018
Category: News
CCTG Trialblazers in the Kingston Mudmoiselle on September 15th

The CCTG Trialblazers will be participating in the Kingston Mudmoiselle on September 15th - running, swimming, and crawling through 5km of mud, dirt and grime in support of the the Canadian Cancer Society!

The money raised from this event helps fund leading-edge cancer research that is improving cancer treatments, preventing cancer and saving lives; provide reliable and up-to-date information on cancer, risk reduction and treatment; offer vital community-based support services for people living with cancer and their families; and advocate for healthy public policies.

Read More